Methodological considerations on CYP2D6 phenoconversion due to drug-drug interaction
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) Editorial |
| Sprache: | Englisch |
| Veröffentlicht: |
10 February 2019
|
| In: |
Clinical pharmacology & therapeutics
Year: 2019, Jahrgang: 105, Heft: 5, Pages: 1076 |
| ISSN: | 1532-6535 |
| DOI: | 10.1002/cpt.1336 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1002/cpt.1336 Verlag, lizenzpflichtig, Volltext: https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1002/cpt.1336 
|
| Verfasserangaben: | Victoria C. Ziesenitz and Gerd Mikus |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1692346644 | ||
| 003 | DE-627 | ||
| 005 | 20220818012335.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200312s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/cpt.1336 |2 doi | |
| 035 | |a (DE-627)1692346644 | ||
| 035 | |a (DE-599)KXP1692346644 | ||
| 035 | |a (OCoLC)1341310239 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Ziesenitz, Victoria C. |d 1985- |e VerfasserIn |0 (DE-588)1036795640 |0 (DE-627)751696099 |0 (DE-576)386865132 |4 aut | |
| 245 | 1 | 0 | |a Methodological considerations on CYP2D6 phenoconversion due to drug-drug interaction |c Victoria C. Ziesenitz and Gerd Mikus |
| 246 | 3 | 0 | |a two six |
| 264 | 1 | |c 10 February 2019 | |
| 300 | |a 1 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 25.06.2020 | ||
| 700 | 1 | |a Mikus, Gerd |e VerfasserIn |0 (DE-588)110903137 |0 (DE-627)691097941 |0 (DE-576)336988710 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical pharmacology & therapeutics |d Hoboken, NJ : Wiley-Blackwell, 1960 |g 105(2019), 5, Seite 1076 |h Online-Ressource |w (DE-627)325793247 |w (DE-600)2040184-X |w (DE-576)094531668 |x 1532-6535 |7 nnas |a Methodological considerations on CYP2D6 phenoconversion due to drug-drug interaction |
| 773 | 1 | 8 | |g volume:105 |g year:2019 |g number:5 |g pages:1076 |g extent:1 |a Methodological considerations on CYP2D6 phenoconversion due to drug-drug interaction |
| 856 | 4 | 0 | |u https://doi.org/10.1002/cpt.1336 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1002/cpt.1336 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200312 | ||
| 993 | |a Editorial | ||
| 994 | |a 2019 | ||
| 998 | |g 110903137 |a Mikus, Gerd |m 110903137:Mikus, Gerd |d 910000 |d 910100 |e 910000PM110903137 |e 910100PM110903137 |k 0/910000/ |k 1/910000/910100/ |p 2 |y j | ||
| 998 | |g 1036795640 |a Ziesenitz, Victoria C. |m 1036795640:Ziesenitz, Victoria C. |d 910000 |d 910500 |e 910000PZ1036795640 |e 910500PZ1036795640 |k 0/910000/ |k 1/910000/910500/ |p 1 |x j | ||
| 999 | |a KXP-PPN1692346644 |e 3607010315 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"recId":"1692346644","language":["eng"],"note":["Gesehen am 25.06.2020"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title_sort":"Methodological considerations on CYP2D6 phenoconversion due to drug-drug interaction","title":"Methodological considerations on CYP2D6 phenoconversion due to drug-drug interaction"}],"person":[{"given":"Victoria C.","family":"Ziesenitz","role":"aut","display":"Ziesenitz, Victoria C.","roleDisplay":"VerfasserIn"},{"family":"Mikus","given":"Gerd","display":"Mikus, Gerd","roleDisplay":"VerfasserIn","role":"aut"}],"relHost":[{"type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"Methodological considerations on CYP2D6 phenoconversion due to drug-drug interactionClinical pharmacology & therapeutics","note":["Gesehen am 18.02.2016"],"recId":"325793247","language":["eng"],"corporate":[{"display":"American Society for Clinical Pharmacology and Therapeutics","roleDisplay":"Herausgebendes Organ","role":"isb"},{"roleDisplay":"Herausgebendes Organ","display":"American Society for Pharmacology and Experimental Therapeutics","role":"isb"}],"pubHistory":["1.1960 -"],"titleAlt":[{"title":"CPT"},{"title":"Clinical pharmacology and therapeutics"}],"part":{"year":"2019","pages":"1076","issue":"5","volume":"105","text":"105(2019), 5, Seite 1076","extent":"1"},"title":[{"title":"Clinical pharmacology & therapeutics","subtitle":"CPT ; official publication of the American Society for Clinical Pharmacology and Therapeutics and the American Society for Pharmacology and Experimental Therapeutics","title_sort":"Clinical pharmacology & therapeutics"}],"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"publisher":"Wiley-Blackwell ; Mosby ; Nature Publ. Group","dateIssuedKey":"1960","dateIssuedDisp":"1960-","publisherPlace":"Hoboken, NJ ; St. Louis, Mo. ; Basingstoke"}],"id":{"issn":["1532-6535"],"eki":["325793247"],"doi":["10.1002/(ISSN)1532-6535"],"zdb":["2040184-X"]}}],"physDesc":[{"extent":"1 S."}],"id":{"doi":["10.1002/cpt.1336"],"eki":["1692346644"]},"origin":[{"dateIssuedKey":"2019","dateIssuedDisp":"10 February 2019"}],"name":{"displayForm":["Victoria C. Ziesenitz and Gerd Mikus"]}} | ||
| SRT | |a ZIESENITZVMETHODOLOG1020 | ||